title: Afatinib Is Active in Platinum-Refractory ERBB-Mutant Urothelial Carcinoma.
abstract: HER2 or ERBB3 alterations are predictive of afatinib response in refractory urothelial carcinomas.
mesh_terms: D000077716:Afatinib; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D009154:Mutation; D010984:Platinum / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D020893:Receptor, ErbB-3 / Q000235:genetics; D016896:Treatment Outcome; D014523:Urethral Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology
chemical_list: D000077716:Afatinib; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D010984:Platinum; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3